Korean Government to reduce biopharmaceutical approval period to half

20 May 2019 - The Korean government plans to reduce by half the current one and a half years of ...

Read more →

Celgene’s myelodysplastic syndrome treatment gets more insurance benefits

7 May 2019 - The Ministry of Health and Welfare has granted additional reimbursement to Celgene’s multiple myeloma drug, Revlimid (ingredient: ...

Read more →

Roche agreed, MSD and BMS should, too

7 May 2019 - Immunotherapies have become so effective and popular that some cancer patients were cured. However, they are ...

Read more →

Biogen’s orphan drug Spinraza to get reimbursement

9 April 2019 - Biogen’s Spinraza (ingredient: nusinersen), a treatment for spinal muscular atrophy (SMA), started to receive insurance benefits as ...

Read more →

HIRA puts brakes on Gilead’s AIDS treatment receiving reimbursement

22 March 2019 - The reimbursement plan for Gilead Science Korea’s Biktarvy, an acquired immune deficiency syndrome (AIDS) treatment, has been ...

Read more →

Reimbursement for orphan drug Spinraza imminent

18 March 2019 - Biogen’s Spinraza (nusinersen), a treatment for spinal muscular atrophy, is likely to obtain reimbursement as early ...

Read more →

Korea’s 30th novel drug K-Cab to get insurance benefit from March

27 February 2019 - Korea’s 30th novel medicine K-Cab Tab. (tegoprazan) will receive insurance coverage, eight months after winning approval, the ...

Read more →

Lung cancer second treatment Alunbrig likely to get insurance coverage

25 February 2019 - The National Health Insurance Service’s drug price assessment committee recently evaluated Takeda’s Alunbrig (briganitib) as eligible ...

Read more →